2024 / 03

Next Paper
DOI: 10.24075/brsmu.2024.021

ORIGINAL RESEARCH

First line therapy for multiple sclerosis: cytokine levels and the impact of herpesvirus infection

Baranova NS1, Gris MS1, Baranov AA1, Spirin NN1, Artyuhov AS2, Kiselev DV1
About authors

1 Yaroslavl State Medical University, Yaroslavl, Russia

2 Pirogov Russian National Research Medical University, Moscow, Russia

Correspondence should be addressed: Natalia S. Baranova
Revolutsionnaya, 5, Yaroslavl, 150000, Russia; ur.liam@sn_avonarab

About paper

Funding: the study was supported by the Foundation for Assistance to Small Innovative Enterprises in Science and Technology (Innovation Promotion Foundation) within the framework of the program UMNIK: Participant of the Youth Research and Innovation Contest (contracts No. 3560GU1/2014 dated 23.09.2014, No. 8815GU2/2015 dated 17.12.2015).

Author contribution: Baranova NS, Gris MS — study planning and design; Gris MS, Artyuhov AS — data acquisition and research procedure; Baranova NS, Gris MS, Baranov AA — data analysis; all authors — data interpretation; Baranova NS, Gris MS — manuscript drafting; all authors — manuscript editing.

Compliance with ethical standards: the study was approved by the local Ethics Committee of the Yaroslavl State Medical University (protocol No. 1 dated 10 October 2013). The informed consent was submitted by all patients.

Received: 2024-04-23 Accepted: 2024-05-05 Published online: 2024-06-19
|
Table 1. Clinical characteristics of patients with MS (Me (25th; 75th percentiles), n = 36)
Note: * — p < 0.05, * * — p < 0.01 compared to the group not treated with DMDs for MS.
Table 2. Serum cytokine levels (Me (25th; 75th percentiles)) of patients with MS and donors
Note: n/s — non-significant differences between groups.
Table 3. Serum cytokine levels (Me (25th; 75th percentiles)) of patients with MS treated with DMDs for MS, who had clinical manifestations/no clinical manifestations of PHVI
Note: * * — р < 0.01 between groups.